Industry: Healthcare Region: Europe Price: US $1million Method of transaction: Equity investment
The company was founded in the UK.
An advanced molecular sieve antivirus mask (AVM) has been introduced to the market, which fully protects the wearer from viruses by filtering virus particles in the range of 60 to 180 nanometres.
It achieves this through a four-layer filter, which is installed as a replacement module in the mask housing, which consists of a nylon housing and a soft silicone interior. The circuit board inside the mask generates a static charge of 30-36 volts and is powered by an external AA battery to keep the mask light and comfortable.
The board is equipped with a microphone and a signal conditioning circuit that can be used in conjunction with a speaker module: this eliminates sound distortion and avoids muffling the wearer's voice. The product patent has been applied for approval.
The product equipment has been ordered, and it is expected to start small-scale production in 2020. All the funds for this stage have been in place.
The next step is to scale up production, either by raising capital or forming partnerships to finance the manufacturing of the product, or by investing in their own capabilities to automate, manufacture and assemble.
The European company now hopes to find a Chinese partner